Antithrombotic effects by oral administration of novel proteinase fraction from earthworm Eisenia andrei on venous thrombosis model in rats.
A novel proteinase fraction, SPP-501, was purified from the earthworm, Eisenia andrei, and its antithrombotic effects compared with those of urokinase and t-PA (tissue type-plasminogen activator) in a thrombosis model, induced by the insertion of a stainless wire coil into the inferior vena cava. SPP-501, urokinase and t-PA were administrated once a day for 14 days. On the oral administration of SPP-501, as well as urokinase and t-PA, the thrombus weight was dramatically decreased. The euglobulin lysis time (ELT) was also shortened by SPP-501, but urokinase and t-PA failed to dissolve the euglobulin clot. Conversely, urokinase and t-PA produced detectable fibrinogen/fibrin degradation products (FDP), but SPP-501 did not. Thrombin induced platelet aggregation was desensitized in the SPP-501 treatment groups. With a high dose of SPP-501 (45 mg/kg), the APTT (activated partial thromboplastin time) was prolonged. These results suggest that SPP-501 shows both antithrombotic and fibrinolytic activities when orally administered.
Lee
Chul Kyu
CK
Central Research Institute, Shin Poong Pharm. Co. Ltd., Ansan, Korea. cklee@shinpoong.co.kr
Shin
Jang Sik
JS
Kim
Byung Su
BS
Cho
Il Hwan
IH
Kim
Young Shik
YS
Lee
Eun Bang
EB
D000284:Administration, Oral; D000818:Animals; D005342:Fibrinolysis / Q000187:drug effects; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D009835:Oligochaeta / Q000201:enzymology*; D010447:Peptide Hydrolases / Q000627:therapeutic use*; D010974:Platelet Aggregation / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D020246:Venous Thrombosis / Q000188:drug therapy*; D014914:Whole Blood Coagulation Time
D005343:Fibrinolytic Agents; D010447:Peptide Hydrolases